ArticleMolecular pharmaceutics2013
How does the cell overcome LCP nanoparticle-induced calcium toxicity?
Article in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Reinforcing Calcium Overload via Inflammation-Mediated Targeting to Amplify Pyroptosis and Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Enhancing Endosomal Escape and Gene Regulation Activity for Spherical Nucleic Acids.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Biodegradable calcium sulfide-based nanomodulators for HActa pharmaceutica Sinica. B · 2022Article
- Article
- Empirical and theoretical insights into the structural effects of selenite doping in hydroxyapatite and the ensuing inhibition of osteoclasts.Materials science & engineering. C, Materials for biological applications · 2020Article
- Co-assembled CaMolecular therapy. Nucleic acids · 2019Article
- Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor.Molecular therapy. Methods & clinical development · 2019Review
- Preparation of CaP/pDNA nanoparticles by reverse micro-emulsion method: Optimization of formulation variables using experimental design.Asian journal of pharmaceutical sciences · 2017Article
- Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery.ACS applied materials & interfaces · 2016Article
- The impact of species and cell type on the nanosafety profile of iron oxide nanoparticles in neural cells.Journal of nanobiotechnology · 2016Article
- Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.Biomaterials · 2016Article
- Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.Theranostics · 2016Review
- Stabilization of a hyaluronate-associated gene delivery system using calcium ions.Biomaterials scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To address the question of how cells respond to the possible Ca(2+) toxicity caused by the release of Ca(2+) into the cytoplasm by LCP nanoparticles, a series of in vitro and in vivo studies using Ca(2+) pump inhibitors were conducted. The results indicated that two major Ca(2+) pumps on the plasma membrane and the mitochondrial membrane, respectively, were able to rapidly respond to the elevated cytosolic Ca(2+) concentration and prevent Ca(2+)-induced apoptosis or necrosis. However, exposure to specific inhibitors of calcium pumps would cause LCP-treated H460 cells to undergo necrosis both in vitro and in vivo. These results demonstrated that the Ca(2+) delivered by LCP was not toxic to cells when the cells contain functional Ca(2+) pumps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.